CONSTANT LEVERAGE LONG - NOVO-NORDISK B | Real-time Euronext Paris 11:13:19 23/05/2024 BST | ||
| 0.48 EUR | +22.14% |
|
| Current month | -48.96% | ||
| 1 month | -41.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 23/05/24 | 0.48 | +22.14% |
| 22/05/24 | 0.393 | -5.30% |
| 21/05/24 | 0.415 | +41.64% |
| 17/05/24 | 0.293 | -14.83% |
| 16/05/24 | 0.344 | -12.69% |
Real-time Euronext Paris
Last update May 23, 2024 at 11:13 am
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| XH9LB | |
| ISIN | NLBNPNL2HAT5 |
| Date issued | 24/08/2023 |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | - € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.685 € |
|---|---|
| Lowest since issue | 0.068 € |
| Spread | 0.012 € |
| Spread % | 2.38% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
923
DKK
Average target price
909.2
DKK
Spread / Average Target
-1.49%
- Stock Market
- Certificates
- XH9LB Certificat
